I think it is too early to judge Adderal sales under kirko’s sales management. He has proven that he was able to cruise through the bridge from Lannett to independence with flying colors.
He may succeed where lannet failed. Same for the new drugs.
Also Nasrat already showed he was able to score impressive gross margins of 53% while penetrating new markets.
Nasrat thinks strategically. He implemented a SAP manufacturing system which is rare for such a small business.
I say we will be surprised by kirko and his team in term of market penetration. .
News 
Market Data 
Discover 
